Project Grant R01HL179005
Award Date
6/25/25
Completion Date
3/31/30
Dollars Obligated
$820K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award of $554,737, provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research program), supports research to identify novel pre-transplant biomarkers associated with the risk of acute rejection in heart transplant recipients. The key objectives are to: 1) validate previously identified protein biomarkers (FGF-2, SPRTY-2, IRAK-1) associated with rejection using proteomic profiling, 2) expand profiling to identify additional proteins...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $804,438 to Inova Health Care Services to conduct a prospective, multicenter study to identify circulating microRNAs that can predict the risk of over- and under-immunosuppression related adverse events in heart transplant patients. The goal is to develop a clinical microRNA score that can provide a quantitative assessment of the patient's net immune state, which...
This federal Project Grant award, totaling $753,813 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to develop novel machine learning techniques for predicting cardiovascular outcomes in patients with clonal hematopoiesis of indeterminate potential (CHIP). The key goals are to use cardiac MRI imaging and genomic data to: 1) Develop a machine learning model to accurately identify CHIP patients and predict their risk...
This Project Grant award of $130,337, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program, supports research to understand the regulation of extramedullary hematopoiesis (EMH) in the liver. The principal investigator will characterize the cellular components of the hematopoietic stem cell (HSC) niche in the EMH liver, identify HSC clones initiating liver EMH, and investigate the role of the splicing regulator RBFOX2...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,564,220 to The Trustees of the University of Pennsylvania to develop an imaging-compatible ex vivo lung perfusion (EVLP) system capable of obtaining structural, functional, and metabolic biomarkers in donor lungs. The project aims to utilize these biomarkers to non-invasively assess donor lungs with common defects, apply injury-specific treatment strategies...
This Project Grant award of $734,607 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to elucidate the key endothelial mechanisms that direct hematopoietic stem cells (HSCs) across the blood vessel wall and into their niche. The research, conducted by Boston Medical Center Corporation, will use high-resolution live cell imaging, structure-function studies, and in vivo proximity-dependent biotinylation in zebrafish to define the endothelial...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $742,810 to the University of Virginia to develop hyperpolarized gas MRI (HGMRI) signatures for detecting and monitoring acute cellular rejection in lung transplant recipients. The 5-year project aims to correlate HGMRI signatures with tissue pathology, treatment response, and single-cell RNA-sequencing data to enhance early...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to evaluate the pathophysiologic relevance of the cytokine IL-39 in the development of graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation. The total award amount is $586,203, with a project period from June 15, 2025 to March 31, 2029. The research will be conducted by the Medical College of Wisconsin, a private non-profit...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) totaling $1,411,136 focuses on characterizing circadian rhythms in organ donors and identifying mechanisms by which donor and recipient circadian clocks affect transplant acceptance, with a focus on lung transplantation. The award aims to: 1) Generate an atlas of brain-dead organ donors' biological rhythms and circadian clock function, and develop a tool to infer circadian...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $126,750 Project Grant (R21HL177578) to the Icahn School of Medicine at Mount Sinai to validate a novel endpoint, the MAGIC Clinical Model and MAGIC Integrated Response, for evaluating acute graft-versus-host disease (GVHD) treatments in clinical trials. The project aims to demonstrate that these new endpoints, measured at Day 14, are more accurate surrogates for...